Bioabsorbable, biobeneficial polyurethanes for use in medical devices
원문보기
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
C07C-265/00
C07C-265/02
C07C-265/04
C07C-265/06
C07C-265/08
C07C-265/10
C07C-265/12
C07C-265/14
출원번호
UP-0115699
(2005-04-26)
등록번호
US-7795467
(2010-10-04)
발명자
/ 주소
Pacetti, Stephen Dirk
Claude, Charles
Astafieva, Irina
출원인 / 주소
Advanced Cardiovascular Systems, Inc.
대리인 / 주소
Squire, Sanders & Dempsey L.L.P.
인용정보
피인용 횟수 :
14인용 특허 :
224
초록
Bioabsorbable, polyurethane-based stent coatings that comprise non-fouling coatings with polyethylene glycol and hyaluronic acid are disclosed. In addition to these coatings, medical devices comprising these coatings and methods of applying the coatings are disclosed.
대표청구항▼
The invention claimed is: 1. A composition comprising: an A-moiety derived from a diisocyanate; a B-moiety derived from a chain extender; and a C-moiety derived from a biobeneficial moiety selected from the group consisting of poly(ethylene glycol), poly(propylene glycol), polyethylene oxide, PEO-P
The invention claimed is: 1. A composition comprising: an A-moiety derived from a diisocyanate; a B-moiety derived from a chain extender; and a C-moiety derived from a biobeneficial moiety selected from the group consisting of poly(ethylene glycol), poly(propylene glycol), polyethylene oxide, PEO-PPO surfactants, PLURONIC surfactants, poly(tetramethylene glycol), amino-terminated PEG, hydroxy functional poly(vinyl pyrrolidone), dextran, dextrin, sulfonated dextran, dermatan sulfate, Silk-elastin protein block-copolymers, sodium hyaluronate, hyaluronic acid, poly(2-hydroxyethyl methacrylate), dihydroxy poly(styrene sulfonate), poly(3-hydroxypropyl methacrylate), poly(3-hydroxypropyl methacrylamide), poly(alkoxy methacrylates), poly(alkoxy acrylates), polyarginine peptides (PAP), phosphoryl choline, heparin, chondroitin sulfate, glycosaminoglycans, chitosan, polyethylene oxide, or any combination of these; wherein: the composition comprises one of the following formulas: wherein x, x′, x″, and x′″ are integers from 1-50,000; A, A′, A″, and A′″ independently represent A-moieties; B, B′, B″, and B′″ independently represent B-moieties; and C and C′ independently represent C-moieties. 2. The composition of claim 1 wherein diisocyanate(s) are selected such that at least one hydrolysis product of the diisocyanate(s) is a biocompatible diamine. 3. The composition of claim 1 wherein the diisocyanate is an aliphatic diisocyanate. 4. The composition of claim 3 wherein the diisocyanate is 1,4-diisocyanatobutane, 1,2-diisocyanatoethane, lysine ester diisocyanate, 1,5-diisocyanatopentane, or any combination of these. 5. The composition of claim 1 wherein the chain extender is biocompatible. 6. The composition of claim 1 wherein the biobeneficial moiety is connected to a hydroxyacid, a hydroxyacid composition, a hydroxyacid oligomer, an amino acid, an amino acid composition, or an amino acid oligomer. 7. The composition of claim 5 wherein the chain extender comprises an alcohol-amine, a diamine, a diol, a dithiol, or any combination of these. 8. The composition of claim 7 wherein the diamine is selected from 1,4-butanediamine, lysine ester, 1,2-ethanediamine, arginine ethyl ester, 1,5-pentanediamine, or any combination of these; or the diol is selected from 1,3-propanediol, 1,2-propanediol, 1,4-butanediol, 1,6-hexanediol, 1,10-decanediol, cyclohexanedimethanol, and poly(caprolactone)diol, 1,5-pentanediol, 1,4-cyclohexanediol, 1,7-heptanediol, 1,8-octanediol, 1,9-nonanediol, 1,12-dodecanediol, poly(caprolactone) diol, or any combination of these. 9. The composition of claim 1 wherein: the A-moiety is derived from a compound with a formula the B-moiety is derived from a compound with a formula W1-Q2-W2; and the C-moiety is derived from a compound with a formula A1-BB-A2 wherein Q1 and Q2 independently represent 1-50 carbon atom moieties; W1 and W2 independently represent O-, S-, or N-containing groups; A1 and A2 independently represent 1-20 carbon-atom hydroxy acids, hydroxy acid oligomers, amino acid, or amino acid oligomers; and BB represents a biobeneficial moiety. 10. The composition of claim 9 wherein Q1 and Q2 independently represent 1-20 carbon atom moieties. 11. The composition of claim 9 wherein W1 and W2 independently represent —OH or —NH2. 12. The composition of claim 9 wherein A1 and A2 independently represent bioabsorbable hydroxy-acid radicals, a metabolic precursor to bioabsorbable hydroxy-acid radicals, bioabsorbable amino acid radicals, or a metabolic precursor to bioabsorbable amino acid radicals. 13. The composition of claim 10 wherein the hydroxyacid is selected from 2-hydroxyacids, 3-hydroxy acids, 4-hydroxy acids, or ε-hydroxy-caproic acid, oligomers of the above, or any combination of these; or the amino acid is glycine, valine, leucine, isoleucine, proline, phenylalanine, oligomers of the above, or any combination of these. 14. The composition of claim 9 wherein the biobeneficial moiety is poly(ethylene glycol), poly(propylene glycol), polyethylene oxide, PEO-PPO surfactants, PLURONIC surfactants, poly(tetramethylene glycol), amino-terminated PEG, hydroxy functional poly(vinyl pyrrolidone), dextran, dextrin, sulfonated dextran, dermatan sulfate, Silk-elastin protein block-copolymers, sodium hyaluronate, hyaluronic acid, poly(2-hydroxyethyl methacrylate), dihydroxy poly(styrene sulfonate), poly(3-hydroxypropyl methacrylate), poly(3-hydroxypropyl methacrylamide), poly(alkoxy methacrylates), poly(alkoxy acrylates), polyarginine peptides (PAP), phosphoryl choline, heparin, chondroitin sulfate, glycosaminoglycans, chitosan, polyethylene oxide, or any combination of these. 15. The composition of claim 1 of the following formula: wherein x is an integer greater than or equal to 1; and mPEG represents a methoxy-poly(ethylene glycol) moiety. 16. A composition comprising a polymer comprising: an A-moiety derived from a diisocyanate, wherein the diisocyanate is 1,4-diisocyanatobutane, 1,2-diisocyanatoethane, lysine ester diisocyanate, 1,5-diisocyanatopentane, or any combination of these; a B-moiety derived from a chain extender comprising an alcohol-amine, diamine, diol or any combination of these wherein the diamine or diol is 1,4-butanediamine, Lysine Ester, 1,2-ethanediamine, Arginine Ethyl Ester, 1,5-pentanediamine, 1,3-propanediol, 1,2-propanediol, 1,4-butanediol, 1,6-hexanediol, 1,10-decanediol, cyclohexanedimethanol, and poly(caprolactone)diol, 1,5-pentanediol, 1,4-cyclohexanediol, 1,7-heptanediol, 1,8-octanediol, 1,9-nonanediol, 1,12-dodecanediol, caprolactone diol, or any combination of these; and a C-moiety derived from a biobeneficial moiety wherein at least one C-moiety is appended from an A moiety as a side chain, the C-moiety comprising: poly(ethylene glycol), poly(propylene glycol), polyethylene oxide, PEO-PPO surfactants, PLURONIC surfactants, poly(tetramethylene glycol), amino-terminated PEG, hydroxy functional poly(vinyl pyrrolidone), dextran, dextrin, sulfonated dextran, dermatan sulfate, Silk-elastin protein block-copolymers, sodium hyaluronate, hyaluronic acid, poly(2-hydroxyethyl methacrylate), dihydroxy poly(styrene sulfonate), poly(3-hydroxypropyl methacrylate), poly(3-hydroxypropyl methacrylamide), poly(alkoxy methacrylates), poly(alkoxy acrylates), polyarginine peptides (PAP), phosphoryl choline, heparin, chondroitin sulfate, glycosaminoglycans, chitosan, polyethylene oxide, or any combination of these, and a hydroxyacid selected from 2-hydroxyacids, 3-hydroxy acids, 4-hydroxy acids, or ε-hydroxy-caproic acid, oligomers of the above, or any combination of these; or the amino acid is glycine, valine, leucine, isoleucine, proline, phenylalanine, oligomers of the above, or any combination of these, wherein the biobeneficial moiety has a maximum molecular weight of 40,000±4,000 Daltons. 17. A medical device comprising at least one type-one polymer, wherein type-one polymers are the compositions of claim 1. 18. A medical device comprising at least one type-one polymer, wherein type-one polymers are the compositions of claim 9. 19. The medical device of claim 17 wherein the type-one polymer is coated onto the surface of the device to form a layer of polymer. 20. The medical device of claim 17 further comprising another type-one polymer, wherein the type-one polymer is disposed on the surface of the device to form a polymer layer and another type-one polymer is disposed on the polymer layer. 21. The medical device of claim 17 further comprising a type-two polymer, wherein type-two polymers are biocompatible and are selected from polycaprolactone, poly(D,L-lactide), poly(L-lactide), poly(D,L-lactide-co-L-lactide), poly(glycolide), poly(D,L-lactide-co-glycolide), poly(dioxanone), poly(4-hydroxybutyrate), poly(3-hydroxybutyrate), poly(3-hydroxy valerate), poly(hydroxybutyrate-co-hydroxyvalerate), poly(tyrosine derive carbonates), poly(tyrosine arylates), poly(imino carbonates), poly(trimethylene carbonate), poly(anhydrides), poly(orthoesters), poly(ester amides) or their mixtures. 22. The medical device of claim 21 comprising at least one inner layer and one outer layer wherein the inner layer is a type-two polymer and the outer layer is a type-one polymer; or the inner layer is a type-one polymer and the outer layer is a type-two polymer. 23. The medical device of claim 17 further comprising at least one therapeutic agent. 24. The medical device of claim 23 wherein the therapeutic agent is selected from proteins, peptides, antiproliferatives, antineoplastics, antiinflammatories, antiplateletes, anticoagulants, antifibrins, antithrombins, antimitotics, antibiotics, antioxidants, or their mixtures. 25. A method of preparing the composition of claim 1 comprising: reacting an amount of hydroxy-acid- or amino-acid-modified biobeneficial composition with an amount of diisocyanate to yield an intermediate; and reacting the intermediate with a chain extender. 26. The method of claim 25 wherein the amount of hydroxy-acid- or amino-acid-modified biobeneficial composition ranges from 0.1 mole % to 100 mole % of the amount of diisocyanate or ranges from 0.1 weight % to 100 weight % of the amount of diisocyanate. 27. The method of claim 26 wherein the amount of hydroxy-acid- or amino-acid-modified biobeneficial composition ranges from 0.33 mole % to 3 mole % of the amount of diisocyanate or ranges from 0.33 weight % to 3 weight % of the amount of diisocyanate. 28. The method of claim 25 wherein the diisocyanate is selected such that the hydrolysis product of the diisocyanate is a biocompatible diamine. 29. The method of claim 28 wherein the diisocyanate is an aliphatic diisocyanate. 30. The method of claim 25 wherein the chain extender is biocompatible. 31. The method of claim 29 wherein the diisocyanate is 1,4-diisocyanatobutane, 1,2-diisocyanatoethane, lysine ester diisocyanate, 1,5-diisocyanatopentane, or any combination of these. 32. The method of claim 30 wherein the chain extender comprises an alcohol-amine, a diamine, a diol, or any combination of these. 33. The method of claim 32 wherein the diamine or diol is 1,4-butanediamine, Lysine Ester, 1,2-ethanediamine, Arginine Ethyl Ester, 1,5-pentanediamine, 1,3-propanediol, 1,2-propanediol, 1,4-butanediol, 1,6-hexanediol, 1,10-decanediol, cyclohexanedimethanol, and poly(caprolactone)diol, 1,5-pentanediol, 1,4-cyclohexanediol, 1,7-heptanediol, 1,8-octanediol, 1,9-nonanediol, 1,12-dodecanediol, caprolactone diol, or any combination of these. 34. The method of claim 25 wherein the biobeneficial moiety is poly(ethylene glycol), poly(propylene glycol), polyethylene oxide, PEO-PPO surfactants, PLURONIC surfactants, poly(tetramethylene glycol), amino-terminated PEG, hydroxy functional poly(vinyl pyrrolidone), dextran, dextrin, sulfonated dextran, dermatan sulfate, Silk-elastin protein block-copolymers, sodium hyaluronate, hyaluronic acid, poly(2-hydroxyethyl methacrylate), dihydroxy poly(styrene sulfonate), poly(3-hydroxypropyl methacrylate), poly(3-hydroxypropyl methacrylamide), poly(alkoxy methacrylates), poly(alkoxy acrylates), polyarginine peptides (PAP), phosphoryl choline, heparin, chondroitin sulfate, glycosaminoglycans, chitosan, polyethylene oxide, or any combination of these. 35. A polymer blend comprising at least two different type-one polymers, wherein type-one polymers are the compositions of claim 1. 36. A polymer blend comprising at least one type-one polymer, wherein type-one polymers are the compositions of claim 1; and the type-two polymer, wherein the type-two polymer is a biocompatible polymer different from the at least one type-one polymer. 37. The polymer blend of claim 36 wherein type-two polymers are polycaprolactone, poly(D,L-lactide), poly(L-lactide), poly(D,L-lactide-co-L-lactide), poly(glycolide), poly(D,L-lactide-co-glycolide), poly(dioxanone), poly(4-hydroxybutyrate), poly(3-hydroxybutyrate), poly(3-hydroxy valerate), poly(hydroxybutyrate-co-hydroxyvalerate), poly(tyrosine derive carbonates), poly(tyrosine arylates), poly(imino carbonates), poly(trimethylene carbonate), poly(anhydrides), poly(orthoesters), poly(ester amides) or their mixtures.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (224)
Bhat, Vinayak D.; Mirzaee, Daryush; Mandrusov, Evgenia; Hossainy, Syed F. A.; Sanders-Millare, Deborra, Actinomycin D for the treatment of vascular disease.
Castro, Daniel; Wu, Steven; Woolbright, Kevin L.; Scheinpflug, Kurt W.; Hossainy, Syed F. A.; Chen, Li, Apparatus and method for depositing a coating onto a surface of a prosthesis.
Daniel Castro ; Steven Wu ; Kevin L. Woolbright ; Kurt W. Scheinpflug ; Syed F. A. Hossainy ; Li Chen, Apparatus and method for depositing a coating onto a surface of a prosthesis.
Bhat, Vinayak D.; Hossainy, Syed F. A.; Mirzaee, Daryush; Mandrusov, Evgenia; Sanders-Millare, Deborra; Guruwaiya, Judy A., Biocompatible carrier containing actinomycin D and a method of forming the same.
Hossainy, Syed F. A.; Sanders-Millare, Deborra; Guruwaiya, Judy A.; Castro, Daniel A.; Harish, Sameer; Wu, Steven Z., Biocompatible coating for a prosthesis and a method of forming the same.
Kohn Joachim B. ; Bolikal Durgadas ; Brode George L. ; Ertel Sylvie I.,FRX ; Guan Shuiyun ; Kemnitzer John E., Biodegradable, anionic polymers derived from the amino acid L-tyrosine.
Eugene P. Goldberg ; Ali Yahiaoui ; Khalid Mentak MA; Theresa Rivero Erickson ; James Seeger, Biofunctional surface modified ocular implants, surgical instruments, medical devices, prostheses, contact lenses and the like.
Viegas Tacey X. (Ann Arbor MI) Reeve Lorraine E. (Dexter MI) Levinson Robert S. (Chesterfield MO), Body cavity drug delivery with thermoreversible gels containing polyoxyalkylene copolymers.
Fearnot Neal E. (West Lafayette IN) Kozma Thomas G. (West Lafayette IN) Ragheb Anthony O. (West Lafayette IN) Voorhees William D. (West Lafayette IN), Coated implantable medical device.
Viegas Tacey X. (Ann Arbor MI) Reeve Lorraine E. (Dexter MI) Levinson Robert S. (Chesterfield MO), Drug delivery by injection with thermoreversible gels containing polyoxyalkylene copolymers.
Eury Robert P. (Cupertino CA) Garguilo Darlene (Fremont CA) Villareal Plaridel (San Jose CA), Drug loaded polymeric material and method of manufacture.
Pavlin Mark S. ; MacQueen Richard C., Ester-terminated polyamides of polymerized fatty acids useful in formulating transparent gels in low polarity liquids.
Lee Keun-Ho (Ithaca NY) Chu Chih-Chang (Ithaca NY), Gamma irradiation sterilizing of biomaterial medical devices or products, with improved degradation and mechanical prope.
Hubbell Jeffrey A. ; Pathak Chandrashekhar P. ; Sawhney Amarpreet S. ; Desai Neil P. ; Hill Jennifer L. ; Hossainy Syed F. A., Gels for encapsulation of biological materials.
Bae You H. (Salt Lake City UT) Okano Teruo (Urayasu UT JPX) Kim Sung W. (Salt Lake City UT), Heterogeneous interpenetrating polymer networks for the controlled release of drugs.
Wu Steven Z. ; Harish Sameer ; Sanders-Millare Deborra ; Guruwaiya Judy A., Implantable medical device having protruding surface structures for drug delivery and cover attachment.
Miller, Kathleen M.; Sydney, Gregory T.; Geitz, Kurt; Dayton, Peter L.; Sahatjian, Ronald A., Implantable or insertable medical device resistant to microbial growth and biofilm formation.
Fox ; Jr. Charles L. (New York NY) Modak Shanta M. (River Edge NJ) Sampath Lester A. (Nyack NY), Infection-resistant compositions, medical devices and surfaces and methods for preparing and using same.
Fox ; Jr. Charles L. (New York NY) Modak Shanta M. (River Edge NJ) Sampath Lester A. (Nyack NY), Infection-resistant compositions, medical devices and surfaces and methods for preparing and using same.
Ashton Paul ; Crooks Peter Anthony ; Cynkowski Tadeusz ; Cynkowska Grazyna ; Guo Hone, Means to achieve sustained release of synergistic drugs by conjugation.
Hostettler Fritz ; Rhum David ; Forman Michael R. ; Helmus Michael N. ; Ding Ni, Medical device coated with interpenetrating network of hydrogel polymers.
Sasaki Masatomi (Shizuoka JPX) Kaneda Shinichi (Shizuoka JPX) Kashiwagi Nobuyoshi (Shizuoka JPX), Medical material containing covalently bound heparin and process for its production.
Koulik Edouard,NLX ; Vincent Larik,NLX ; Cahalan Patrick,NLX ; Fogt Eric ; Ishihara Kazuhiko,JPX ; Nakabayashi Nobuo,JPX, Method for making biocompatible medical article.
Zhong Sheng-Ping (Farum DKX), Method of providing a substrate with a hydrophilic coating and substrates, particularly medical devices, provided with s.
Hubbell Jeffrey A. (Austin TX) Elbert Donald (Austin TX) Hill-West Jennifer L. (Austin TX) Drumheller Paul D. (Austin TX) Chowdhury Sanghamitra (Round Rock TX) Sawhney Amarpreet (Newton MA), Multifunctional organic polymers.
Fitzhugh, Anthony L.; Cheng, Peiwen; Saavedra, Joseph; Cafferata, Robert; Hendriks, Marc; Keefer, Larry K.; Tedeschi, Eugene; Verhoeven, Michel I. P. M., Nitric oxide-releasing metallic medical devices.
Hayes Kathryn S. (Norristown PA) Frihart Charles R. (Lawrenceville NJ) Wroczynski Ronald J. (Pittsfield MA), Novel poly(ester-amide) hot-melt adhesives.
Viegas Tacey X. (Ann Arbor MI) Reeve Lorraine E. (Ann Arbor MI) Levinson Robert S. (Saline MI), Ophthalmic drug delivery with thermoreversible polyoxyalkylene gels adjustable for pH.
Clapper David L. ; Swanson Melvin J. ; Hu Sheau-Ping ; Amos Richard A. ; Everson Terrence P., Polybifunctional reagent having a polymeric backbone and photoreactive moieties and bioactive groups.
Tartaglia Joseph M. (Redwood City CA) Loeffler Joseph P. (Mountain View CA) Turnlund Todd H. (Mountain View CA), Polymer film for wrapping a stent structure.
Tondeur Carole,FRX ; Riess Henri-Gerard,FRX ; Meybeck Alain,FRX ; Tranchant Jean-Francois,FRX, Polymers functionalized with amino acids or amino acid derivatives, method for synthesizing same, and use thereof as sur.
Cohn Daniel (Jerusalem ILX) Yitzchaiek Shlomo (Ramat Gan ILX) Bilenkis Sophie (Jerusalem ILX), Polyurethane-based polymeric materials and biomedical articles and pharmaceutical compositions utilizing the same.
Leidner Jacob,CAX ; Amellal Karim,CAX, Porous protheses and methods for making the same wherein the protheses are formed by spraying water soluble and water insoluble fibers onto a rotating mandrel.
Hostettler Fritz ; Rhum David ; Forman Michael R. ; Helmus Michael N. ; Ding Ni, Process for preparation of slippery, tenaciously adhering, hydrophilic polyurethane hydrogel coating, coated polymer and metal substrate materials, and coated medical devices.
Marchant Roger E. (Shaker Hts. OH), Process for producing hydroxylated plasma-polymerized films and the use of the films for enhancing the compatiblity of b.
Myers Michael R. ; Spada Alfred P. ; Persons Paul E. ; Maguire Martin P., Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56.sup.lck tyrosine kinases.
Alfred P. Spada ; Wei He ; Michael R. Myers, Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases.
He Wei ; Myers Michael R. ; Spada Alfred P., Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases.
Myers Michael R. ; He Wei ; Spada Alfred P. ; Maguire Martin P., Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases.
Myers, Michael R.; He, Wei; Spada, Alfred P.; Maguire, Martin P., Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases.
Myers, Michael. R.; Spada, Alfred P.; Persons, Paul E.; Maguire, Martin P., Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases.
Lee Keun H. (Ithaca NY) Won Chee Y. (Ithaca NY) Chu Chih-Chang (Ithaca NY), Reactive graft polymer with biodegradable polymer backbone and method for preparing reactive biodegradable polymers.
Bates, Brian L.; Fearnot, Neal E.; Kozma, Thomas G.; Osborne, Thomas A.; Ragheb, Anthony O.; Roberts, Joseph W.; Voorhees, III, William D., Silver implantable medical device.
Ragheb Anthony O. ; Bates Brian L. ; Fearnot Neal E. ; Osborne Thomas A. ; Kozma Thomas G. ; Roberts Joseph W. ; Voorhees ; III William D., Silver implantable medical device.
Mandrusov, Evgenia; Consigny, Paul; Hossainy, Syed Faiyaz Ahmed; Mirzaee, Dary, Stent for increasing blood flow to ischemic tissues and a method of using the same.
Pinaki Ray ; Vinayak D. Bhat ; Daryush Mirzaee, Substance delivery apparatus and a method of delivering a therapeutic substance to an anatomical passageway.
Rudolph Alan S. ; Chu Chih-Chang ; Stenger David A. ; Spargo Barry J. ; Georger Jacque, Surface modification of polymers with self-assembled monolayers that promote adhesion, outgrowth and differentiation of.
Shalaby Shalaby W. (Lebanon NJ) Jamiolkowski Dennis D. (Long Valley NJ), Surgical devices of polyesteramides derived from bis-oxamidodiols and dicarboxylic acids.
Fearnot Neal E. (West Lafayette IN) Ragheb Anthony O. (West Lafayette IN) Voorhees ; III William D. (West Lafayette IN), Thrombolytic treated intravascular medical device.
Viegas Tacey X. (Canton MI) Reeve Lorraine E. (Dexter MI) Levinson Robert S. (Chesterfield MO), Topical drug delivery with polyoxyalkylene polymer thermoreversible gels adjustable for pH and osmolality.
Hossainy, Syed F. A.; Tang, Fuh-Wei; Kleiner, Lothar W.; Glauser, Thierry; Tang, Yiwen; Roorda, Wouter E.; Pacetti, Stephen D.; Zhang, Gina; Chen, Yung-Ming; McNiven, Andrew F.; McNiven, Sean A.; Yoe, Brandon J., Methods of treatment of polymeric coatings for control of agent release rates.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.